Edition:
India

Flex Pharma Inc (FLKS.OQ)

FLKS.OQ on NASDAQ Stock Exchange Global Market

3.92USD
23 Jan 2018
Change (% chg)

$0.04 (+1.03%)
Prev Close
$3.88
Open
$3.87
Day's High
$4.13
Day's Low
$3.81
Volume
34,078
Avg. Vol
10,653
52-wk High
$5.83
52-wk Low
$2.68

Chart for

About

Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company's product candidates activate certain receptors in primary sensory neurons, which then act... (more)

Overall

Beta: --
Market Cap(Mil.): $60.74
Shares Outstanding(Mil.): 17.97
Dividend: --
Yield (%): --

Financials

BRIEF-Flex Pharma Engaged Investment Banking Firm To Assist With Consideration Of Strategic Alternatives For Co's Hotshot Consumer Product Business‍​

* FLEX PHARMA - ENGAGED INVESTMENT BANKING FIRM TO ASSIST WITH CONSIDERATION OF STRATEGIC ALTERNATIVES FOR CO'S HOTSHOT CONSUMER PRODUCT BUSINESS‍​ Source text: (http://bit.ly/2F0i8Tu) Further company coverage:

22 Jan 2018

BRIEF-Flex Pharma Inc - ‍Completed Enrollment In Its Phase 2 Exploratory Spasticity Study In Multiple Sclerosis With Approximately 50 Patients In Australia​

* FLEX PHARMA INC - ‍COMPLETED ENROLLMENT IN ITS PHASE 2 EXPLORATORY SPASTICITY STUDY IN MULTIPLE SCLEROSIS WITH APPROXIMATELY 50 PATIENTS IN AUSTRALIA​ Source text for Eikon: Further company coverage:

28 Nov 2017

BRIEF-Flex Pharma Q3 loss per share $0.54

* Q3 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S

06 Nov 2017

BRIEF-Flex Pharma reports positive topline data from exploratory phase 2 trial of FLX-787 in ALS

* Flex Pharma reports positive topline data from exploratory phase 2 trial of FLX-787 in ALS

06 Nov 2017

BRIEF-Flex Pharma initiates CMT phase 2 trial with FLX-787 in US

* Flex Pharma Inc - ‍expects to report topline results from this study in middle of 2018​ Source text for Eikon: Further company coverage:

16 Oct 2017

BRIEF-Flex Pharma says on Aug 23, board unanimously voted to increase the size of co's board of directors to nine members ‍​- SEC filing

* Flex Pharma says on Aug 23, board unanimously voted to increase the size of co's board of directors to nine members ‍​- SEC filing

29 Aug 2017

BRIEF-Flex Pharma Q2 loss per share $0.51

* Q2 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S

02 Aug 2017

BRIEF-Flex Pharma initiates ALS phase 2 trial with flx-787 in U.S.

* Says expects to report topline results from this study in middle of 2018

01 Aug 2017

BRIEF-Flex Pharma names William Mcvicar president and chief executive officer

* Flex pharma names William Mcvicar president and chief executive officer

31 Jul 2017

BRIEF-FDA grants fast track designation to Flex Pharma’s FLX-787

* FDA grants fast track designation to Flex Pharma’s FLX-787 for the treatment of severe muscle cramps associated with ALS

25 Jul 2017

Earnings vs. Estimates